Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity.[1] The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees.[2] In 2018, they opened a subsidiary in the US.[3] Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley.[4]
History
Zealand Pharma A/S was founded by Bjarne Due Larsen, Lars Hellerung Christiansen, Leif Helth Jensen, Dan Buxbom, and Florian Schönharting in 1997 as Peptide Probe Technologies ApS, a biopharmaceutical company focused on the design and development of peptide-based medicine.[5]